Kiniksa Pharmaceuticals Interna (KNSA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Kiniksa Pharmaceuticals Interna

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$77.62+2.47(0.03%)Pre-market

Market Cap

$6.15B

P/E

76.3x

P/S

7.3x

P/B

9.4x

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

How this company scores

GoodMetricSide Score: 79/100

Strongest: Cash & Earnings Quality (24/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability18/25

Growth22/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality24/25

Strengths

Growing revenueRising free cash flowRising earningsInterest easily covered

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 76.3x5y range 3.8x – 424.2x

Currently above its 11-quarter median.

P/S · 7.3x5y range 3.2x – 39.5x

Currently above its 20-quarter median.

P/B · 9.4x5y range 1.9x – 9.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Share Dilution

Red Flag

Shares outstanding increased 8.2% — significant dilution, likely from stock compensation or capital raises.

Price & Volume

Market Cap $6.15B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $840.85M
Q. Revenue: $243.60M
TTM EBITDA: $100.25M
TTM Op. Income: $100.25M
Q. Op. Income: $27.19M
TTM Net Income: $80.66M
Q. Net Income: $25.43M
EPS: $0.33
Shares Out.: $77.58M

$840.85M in TTM revenue grew 58.9% YoY, reaching $243.60M last quarter. TTM EBITDA of $100.25M and TTM operating income of $100.25M show growth is flowing through to the bottom line. TTM net income of $80.66M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 90.3%
EBITDA Margin: 11.2%
Op. Margin: 11.2%
Net Margin: 10.4%

Op. margin of 11.2% is down 1.7% YoY — costs are rising relative to revenue. Net margin at 10.4% and gross margin of 90.3% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 13% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 76.3x
P/S Ratio: 7.3x
P/B Ratio: 9.4x

At 76.3x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 7.3x and P/B of 9.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 82% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $896.11M
Cash: $175.68M
Long-Term Debt: N/A
Book Value: $654.15M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $47.20M
TTM Free Cash Flow: $182.84M
FCF Margin: 21.7%
FCF / Net Income: 2.3

TTM FCF of $182.84M on $47.20M in operating cash flow. The FCF / Net Income ratio of 2.3x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.